A PYMNTS Company

US: Moody’s report finds generic drug market faces consolidation

By  |  August 8, 2013

A recent report by Moody’s Investor Service found that following regulatory crackdowns on the pharmaceutical market, the generic drug industry will likely experience rapid consolidation in the near future. According to Moody’s, the recent US Supreme Court decision, which found that drug makers can face lawsuits regarding pay-for-delay agreements, will lead to an influx of Federal Trade Commission scrutiny over the industry as well as class action litigation, many such cases have been on hold since before the Supreme Court ruling. The result, said Moody’s, means threats of large liabilities that – along with other factors – could lead generic drug makers to consolidate as purchasers and regulators seek damages. The report cites last week’s decision by Teva Pharmaceuticals to settle over such an antitrust case for $485 million.

    Get the Full Story

    Complete the form to unlock this article and enjoy unlimited free access to all PYMNTS content — no additional logins required.

    yesSubscribe to our daily newsletter, PYMNTS Today.

    By completing this form, you agree to receive marketing communications from PYMNTS and to the sharing of your information with our sponsor, if applicable, in accordance with our Privacy Policy and Terms and Conditions.

    Full Content: Forbes

    We’d love to be your preferred source for news.

    Please add us to your preferred sources list so our news, data and interviews show up in your feed. Thanks!

    Add as Preferred Source

    Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.